Veracyte, Inc. (NASDAQ:VCYT - Free Report) - Equities research analysts at William Blair upped their Q2 2025 earnings per share estimates for Veracyte in a report released on Tuesday, May 13th. William Blair analyst A. Brackmann now expects that the biotechnology company will post earnings of $0.19 per share for the quarter, up from their prior estimate of $0.18. The consensus estimate for Veracyte's current full-year earnings is $0.68 per share. William Blair also issued estimates for Veracyte's Q3 2025 earnings at $0.19 EPS, Q4 2025 earnings at $0.25 EPS, FY2025 earnings at $0.80 EPS, Q1 2026 earnings at $0.13 EPS, Q2 2026 earnings at $0.21 EPS, Q3 2026 earnings at $0.23 EPS, Q4 2026 earnings at $0.31 EPS and FY2026 earnings at $0.88 EPS.
Several other analysts also recently issued reports on the stock. UBS Group dropped their target price on Veracyte from $49.00 to $42.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Stephens reissued an "overweight" rating and issued a $45.00 target price on shares of Veracyte in a report on Wednesday, March 26th. StockNews.com downgraded shares of Veracyte from a "buy" rating to a "hold" rating in a research note on Wednesday, February 26th. Craig Hallum started coverage on Veracyte in a research report on Thursday, March 20th. They set a "buy" rating and a $45.00 price objective for the company. Finally, Guggenheim decreased their target price on shares of Veracyte from $45.00 to $37.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $40.90.
Check Out Our Latest Analysis on Veracyte
Veracyte Price Performance
Veracyte stock traded down $1.05 during mid-day trading on Friday, hitting $27.76. The company's stock had a trading volume of 358,155 shares, compared to its average volume of 888,229. The stock has a market cap of $2.17 billion, a price-to-earnings ratio of -184.89 and a beta of 2.14. The business has a 50 day moving average price of $30.75 and a 200-day moving average price of $36.95. Veracyte has a 12 month low of $19.73 and a 12 month high of $47.32.
Veracyte (NASDAQ:VCYT - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The biotechnology company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.07. The business had revenue of $118.63 million for the quarter, compared to analyst estimates of $110.73 million. Veracyte had a positive return on equity of 3.02% and a negative net margin of 2.18%. During the same period last year, the firm posted ($0.39) earnings per share.
Institutional Investors Weigh In On Veracyte
Institutional investors and hedge funds have recently modified their holdings of the company. Barclays PLC raised its stake in Veracyte by 138.6% during the third quarter. Barclays PLC now owns 146,402 shares of the biotechnology company's stock worth $4,983,000 after acquiring an additional 85,033 shares during the period. Avanza Fonder AB bought a new position in Veracyte during the 4th quarter valued at about $1,379,000. Legal Advantage Investments Inc. acquired a new stake in shares of Veracyte in the 4th quarter valued at $250,000. KBC Group NV grew its position in shares of Veracyte by 44.6% during the 4th quarter. KBC Group NV now owns 3,872 shares of the biotechnology company's stock worth $153,000 after buying an additional 1,195 shares during the period. Finally, Baader Bank Aktiengesellschaft bought a new position in Veracyte in the fourth quarter valued at approximately $262,000.
About Veracyte
(
Get Free Report)
Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.
See Also
Before you consider Veracyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veracyte wasn't on the list.
While Veracyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
